Clinical Trial Search

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Medication Adherence - Pill Count — 0.46; 0.53 Probability of adherence (PT/PP => 0.8) — p=0.04

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Statin Adherence — 86; 85; 86; 85 percentage of correct statin doses

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Change in Medication Adherence as Measured by the Adherence to Refills and Medications Scale (ARMS) — -4.0; -1.0 score on a scale

Primary: Feasibility of AMDD to Improve Medication Adherence Via Completion Rate — 15 participants

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days

Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03

Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Medication Possession Ratio at Baseline — 65.0 percentage of medication possession

Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation

Primary: Adherence to Medication — 2; 3 Participants

Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001

Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001

Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken

Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale

Primary: Electronically Measured Mean Medication Adherence During Intervention — 87; 95; 92 Percentage of Timely Med Adherence

Primary: Probability of Resolution of Nonadherence Within 30 Days — .4286; .4290; .4554; .4437 Proportion of resolved NAEs within 30 — p=<0.01

Primary: Change in Self Reported Medication Adherence — 0.78; 0.74; 0.53; 0.62 Scores on a scale — p=0.22

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Change in Treatment Non-adherence as Measured by the Tablets Routine Questionnaire (TRQ) (Past Month) — -23.6 percentage of medication not taken — p=<0.001

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Adherence to Anti-retroviral Therapy — 0.69; 0.73; 0.62; .67 proportion adherence